Novartis Paid More than $1 Million to Firm Linked to Trump Lawyer

The drug company had an agreement with Essential Consultants, run by the president’s former attorney Michael Cohen.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ISTOCK/HOHLNovartis reportedly paid Essential Consultants, a company run by President Donald Trump’s former personal attorney Michael Cohen, $1.2 million, but has since ended a contract with the firm, according to Reuters.

The drug company entered into the agreement with Essential Consultants in February 2017 because it “believed that Michael Cohen could advise the company as to how the Trump administration might approach certain U.S. healthcare policy matters, including the Affordable Care Act,” Novartis spokeswoman Sofina Mirza-Reid tells The Washington Post.

Michael Avenatti, a lawyer for a porn star who received $130,000 from Essential Consultants as hush money after having an alleged affair with Trump before he became president, recently revealed the connection between Cohen’s company and Novartis’s payments. Documents linked to by STAT show that a unit of the drug firm called Novartis Investment SARL made about four payments of nearly $100,000 each to Essential Consultants on October 5, 2017, November 3, 2017, December 1, 2017, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Ashley Yeager

    Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours